New or worsening anaemia or thrombocytopenia affects outcomes in JAKi-naive myelofibrosis patients treated with ruxolitinib

Authors
Category Primary study
Conference66th Annual Scientific Meeting of the British Society for Haematology
Year 2026
This article has no abstract
Epistemonikos ID: 678c4eb89e31753d94246433e7ea57042c6bd784
First added on: Sep 05, 2026